-

Medincell Aligns Debt Maturity with Its Expected Revenue Growth Trajectory

More than 3 years extension of debt maturity to mid-2031, aligning it with expected revenue ramp-up primarily driven by marketed UZEDY® and Olanzapine LAI, which is currently under regulatory review in the U.S. and Europe

€28 million in non-dilutive new bank loans secured from leading European commercial banks

Early repayment of half of the €40 million European Investment Bank (EIB) credit facility and the related capitalized interest, originally maturing in December 2027

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align debt maturities with the Company's expected revenue growth trajectory and future cash flows. These cash flows are expected to be primarily driven by milestones and royalties from UZEDY®, which is already marketed, and from Olanzapine LAI, currently under regulatory review in the U.S., with approval anticipated in Q4 2026. Both products are partnered with Teva.

The Company has secured €28 million in non-dilutive loans with leading European commercial banks, with no covenant or equity-linked instruments attached, strengthening its long-term cash position. In parallel, the Company will repay a €20 million tranche, together with related capitalized interests, of its existing €40 million European Investment Bank (EIB) credit facility entered into in 2022, by the end of July 2026.

Christophe Douat, CEO of Medincell, said: “This is a natural step in executing our ‘Shift to Growth’ strategy. As UZEDY sales continue to ramp up and we move closer to the potential commercial launch of Olanzapine LAI by our partner Teva, we are aligning our financial structure with our expected revenue growth. This strengthens our flexibility and supports the continued advancement of our pipeline of innovative products, aimed at generating recurring, high-margin revenues over time and creating sustainable long-term value.”

For more information, please click here: https://www.medincell.com/news/

About Medincell
medincell.com

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Chief Strategy Officer, U.S. Finance
grace.kim@medincell.com / +1 (646) 991-4023

Industry:

Medincell

BOURSE:MEDCL
Release Versions
English

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Chief Strategy Officer, U.S. Finance
grace.kim@medincell.com / +1 (646) 991-4023

More News From Medincell

Medincell Appoints Edna Venneker, MD, as Chief Medical Officer

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext: MEDCL), a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas, today announced the appointment of Edna Venneker, MD, as Chief Medical Officer. Edna Venneker brings extensive international experience in drug development, spanning non-clinical and clinical strategy, regulatory affairs, program execution and portfolio decision-mak...

Medincell Appoints Edna Venneker, MD, as Chief Medical Officer

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext: MEDCL), a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas, today announced the appointment of Edna Venneker, MD, as Chief Medical Officer. Edna Venneker brings extensive international experience in drug development, spanning non-clinical and clinical strategy, regulatory affairs, program execution and portfolio decision-making. Most recentl...

Medincell’s Dr Grace Kim to Participate in Piper Sandler CNS Symposium

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026. Dr Kim will engage with investors in a fireside discussion led by Piper Sandler a...
Back to Newsroom